Use of KW-2189, a DNA minor groove-binding agent, in patients with hepatocellular carcinoma: A north central cancer treatment group (NCCTG) phase II clinical trial

Journal of Gastrointestinal Cancer

Volumn 38, Issue 1, 2007, Pages 10-14

  Alberts, Steven R ^a   Suman, Vera J ^a   Pitot, Henry C ^a   Camoriano, John K ^b   Rubin, Joseph ^a  

^a MAYO CLINIC   (United States)

^b Scottsdale CCOP   (United States)

Author keywords

Chemotherapy; Clinical trial; DNA minor groove binding agent; Hepatocellular carcinoma; Metastatic

Indexed keywords

PIBROZELESIN; 2 PYRROLIDONE DERIVATIVE; ANTINEOPLASTIC AGENT;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLEEDING; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOLOGY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; HUMAN; JAUNDICE; LEUKOPENIA; LIVER CARCINOMA; LIVER CELL CARCINOMA; LIVER HISTOLOGY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; KAPLAN MEIER METHOD; LIVER TUMOR; MIDDLE AGED; MORTALITY; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; PYRROLIDINONES; TREATMENT OUTCOME;

EID: 59149086480     PISSN: 19416628     EISSN: 19416636     Source Type: Journal    
DOI: 10.1007/s12029-007-9007-6     Document Type: Article

References (27)

1. E Mor RT Kaspa P Sheiner M Schwartz 1998 Treatment of hepatocellular carcinoma associated with cirrhosis in the era of liver transplantation Ann Intern Med. 129 643 653 (Pubitemid 28480821)
2. RG Simonetti A Liberati C Angiolini L Pagliaro 1997 Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials Ann Oncol. 8 117 136 (Pubitemid 27112878)
3. M Ichimura T Ogawa S Katsumata K-I Takahashi I Takahashi H Nakano 1991 Duocarmycins, new antitumor antibiotics produced by Streptomyces; producing organisms and improved production J Antibiotics. 44 1045 1053
4. M Ichimura T Ogawa K-I Takahashi E Kobayashi I Kawamoto T Yasuzawa 1990 Duocarmycin SA, a new antitumor antibiotic from Streptomyces sp J Antibiotics. 43 1037 1038 (Pubitemid 20274070)
5. T Ogawa M Ichimura S Katsumata M Morimoto K Takahashi 1989 New antitumor antibiotics, duocarmycins B1 and B2 J Antibiotics. 42 1299 1301
6. I Takahashi K-I Takahashi M Ichimura M Morimoto K Asano I Kawamoto 1988 Duocarmycin A, a new antitumor antibiotic from Streptomyces J Antibiotics. 41 1915 1917 (Pubitemid 19010363)
7. DL Boger DS Johnson 1995 CC-1065 and the duocarmycins: unraveling the keys to a new class of naturally derived DNA alkylating agents Proc Natl Acad Sci USA. 92 3642 3649
8. A Okamoto A Asai H Saito M Okabe K Gomi 1994 Differential effect of duocarmycin A and its novel derivative DU-86 on DNA strand breaks in HeLa S3 cells Jpn J Cancer Res. 85 1304 1311
9. LH Hurley VL Reynolds DH Swenson GL Petzold TA Scahill 1984 Reaction of the antitumor antibiotic CC-1065 with DNA: structure of a DNA adduct with DNA sequence specificity Science. 226 843 844 (Pubitemid 15200678)
10. T Yasuzawa K-I Muroi M Ichimura I Takahashi T Ogawa K Takahashi 1995 Duocarmycins, potent antitumor antibiotics produced by Steptomyces sp. structures and chemistry Chem Pharm Bull. 43 378 391
11. E Kobayashi A Okamoto M Asada M Okabe S Nagamura A Asai 1994 Characteristics of antitumor activity of KW-2189, a novel water-soluble derivative of duocarmycin, against murine and human tumors Cancer Res. 54 2404 2410 (Pubitemid 24138732)
12. EG Adams GJ Badiner BK Bhuyan 1988 Effects of U-71,184 and several other CC-1065 analogues on cell survival and cell cycle of Chinese hamster ovary cells Cancer Res. 48 109 116 (Pubitemid 18030338)
13. SR Alberts C Erlichman JM Reid JA Sloan MM Ames RL Richardson 1998 Phase I study of the duocarmycin semisynthetic derivative KW-2189 given daily for five days every six weeks Clin Cancer Res. 4 2111 2117 (Pubitemid 28415655)
14. J Abbruzzese T Madden R Newman 1996 Phase I clinical and pharmacokinetic trial of KW2189 in patients with solid tumors (meeting abstract) Proc Annu Meet Am Assoc Cancer Res. 37 A1138
15. TR Fleming 1982 One-sample multiple testing procedure for phase II clinical trials Biometrics. 38 143 151
16. T Therneau H Weiand M Chang 1990 Optimal designs for a grouped sequential binomial trial Biometrics. 46 771 781
17. M Cristofanilli WJ Bryan LL Miller AY Chang WJ Gradishar DW Kufe 1998 Phase II study of adozelesin in untreated metastatic breast cancer Anti-Cancer Drugs. 9 779 782 (Pubitemid 28512884)
18. HA Burris VC Dieras M Tunca RH Earhart JR Eckardt GI Rodriguez 1997 Phase I study with the DNA sequence-specific agent adozelesin Anti-Cancer Drugs. 8 588 596 (Pubitemid 27373438)
19. BJ Foster PM LoRusso E Poplin M Zalupski M Valdivieso A Wozniak 1996 Phase I trial of Adozelesin using the treatment schedule of daily x5 every 3 weeks Invest New Drugs. 13 321 326
20. GJ Shamdas DS Alberts M Modiano C Wiggins J Power DA Kasunic 1994 Phase I study of adozelesin (U-73,975) in patients with solid tumors Anti-Cancer Drugs. 5 10 14 (Pubitemid 24066556)
21. HC Pitot JM Reid JA Sloan MM Ames AA Adjei J Rubin 2002 A Phase I study of bizelesin (NSC 615291) in patients with advanced solid tumors Clin Cancer Res. 8 712 717 (Pubitemid 34742099)
22. GH Schwartz A Patnaik LA Hammond J Rizzo K Berg DD Von Hoff 2003 A phase I study of bizelesin, a highly potent and selective DNA-interactive agent, in patients with advanced solid malignancies Ann Oncol. 14 775 782 (Pubitemid 36621779)
23. N Pavlidis S Aamdal A Awada H Calvert P Fumoleau R Sorio 2000 Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG) Cancer Chemother Pharmacol. 46 167 171 (Pubitemid 30624849)
24. A Awada CJ Punt MJ Piccart O Van Tellingen L Van Manen J Kerger 1999 Phase I study of Carzelesin (U-80,244) given (4-weekly) by intravenous bolus schedule Brit J Cancer. 79 1454 1461 (Pubitemid 29116804)
25. O van Tellingen CJ Punt A Awada DJ Wagener MJ Piccart Y Groot 1998 A clinical pharmacokinetics study of carzelesin given by short-term intravenous infusion in a phase I study Cancer Chemother Pharmacol. 41 377 384 (Pubitemid 28095753)
26. SN Markovic VJ Suman AM Vukov TR Fitch DW Hillman AA Adjei 2002 Phase II trial of KW2189 in patients with advanced malignant melanoma Am J Clin Oncol. 25 308 312 (Pubitemid 34602558)
27. EJ Small R Figlin D Petrylak DJ Vaughn O Sartor I Horak 2000 A phase II pilot study of KW-2189 in patients with advanced renal cell carcinoma Invest New Drugs. 18 193 197 (Pubitemid 30261291)